53-year-old woman with a history of asthma, depression and moderate-toheavy consumption of alcohol had presented to the emergency department with a threemonth history of increasing fatigue and jaundice. She had reported consuming three or four beers on a regular basis and a few glasses of wine three times weekly. Over the past three months, she had been taking six prescription medications (Table 1) 1-3 and seven natural health products (Table 2) . [4] [5] [6] [7] [8] [9] [10] [11] [12] Her bilirubin level had been elevated (281 [normal 3.4-22] µmol/L), as had her liver enzyme levels (alanine transaminase 755 [normal ] U/L and alkaline phosphatase 273 [normal 42-98] U/L). An ultrasound of her abdomen had been consistent with cirrhosis, and the presumptive diagnosis had been cirrhotic liver disease. She had been advised to stop using alcohol and all of the natural health products.
Despite taking this advice, the patient's jaundice and fatigue worsened. She presented to the emergency department 12 days later, at which time she was admitted to hospital. Her physical exam showed asterixis, spider nevi and ascites, and she seemed mildly confused. A test showed that she was immune to hepatitis B. A blood test for hepatitis C was negative. Her levels of ceruloplasmin, α-1 antitrypsin, anti mitochondrial antibodies, antinuclear antibody, and antismoothmuscle antibody were normal. Her immunoglobulin levels were elevated (immunoglobulin G 20.4 [normal 6.94-16.18 ] g/L, immunoglobulin A 6.11 [normal 0.70-4.00] g/L and im munoglobulin M 3.15 [normal 0.60-3.00] g/L). Her liver function tests remained abnormal (bilirubin 441 µmol/L, alanine transaminase 317 U/L and alkaline phosphatase 247 U/L), and a repeat ultrasound of her abdomen was still consistent with cirrhosis. There was no evidence of thrombosis in the hepatic or portal veins and no biliary dilatation. A transjugular biopsy of the liver showed submassive necrosis without the features of alcoholic hepatitis (Figure 1 ).
The differential diagnosis was submassive hepatic necrosis causing hepatic encephalopathy, due to either autoimmune hepatitis or drug toxicity. Liver injury as a result of alcohol use was considered unlikely because of the patient's very high level of alanine transaminase and the results of the biopsy of her liver. A timeline showing the patient's use of prescription and nonprescription medications is shown in Figure 2 .
The patient's condition eventually improved with treatment that included diuretics, lactulose and prednisone, followed by azathioprine.
The case of this patient was evaluated through the multicentre Pharmacy Study of Natural Health Product Adverse Reactions (SONAR). 13 We concluded that the entire combination of drugs, nat ural products and alcohol taken by our patient was possibly related to her hepatic symptoms. A single caus ative agent could not be isolated.
Discussion
It is important to determine potential adverse events that may be caused by medications, natural health products or illicit drugs, or combinations. Both passive and active surveillance can provide information on adverse reactions.
Passive surveillance usually requires health care professionals and patients to voluntarily report adverse events. Passive surveillance accounts for most of the postmarketing reporting of adverse events in Canada. The major drawbacks of passive surveillance are that meaningful estimates of inci-dence cannot be generated, the quality of reports tends to be low and it is well-known for underreporting. 14 In contrast, active surveillance involves protocol-driven screening of risk groups, which in turn allows for more accurate estimates of incidence and the generation of reports that are more consistent and of a higher quality. 4 This case demonstrates an example of active surveillance. This type of process can be used to assess potential adverse events caused by medications or natural health products. It also illustrates the considerable uncertainties in using case reports to determine potential adverse effects.
Step 1: Collection of information and review of adverse event databases We completed a comprehensive review of the pubished literature (using the Medline and EMBASE search engines) on all prescription medications and natural health products used by the patient. Several of the natural health products have been associated with hepatotoxicity; however, much of the information about these associations is from studies done on animals or in vitro, and precise dosage information is limited. [4] [5] [6] [7] [8] [9] [10] [11] [12] 15 Both venlafaxine and varenicline have been reported to cause hepatotoxicity in patients, especially in those with underlying liver conditions. [1] [2] [3] Tables 1 and 2 provide summaries of the patient's medications and any published evidence of hepatotoxicity associated with their use.
Step 2: Analysis of medications The harms associated with natural health products may be due to ingredients that are not listed on their labels (i.e., contaminants). Samples of all of the natural health products taken by our patient, with the exception of the human growth hormone product (GHR), which was no longer available in Canada, were tested for the possible presence of contaminants. Multiple samples of conjugated linoleic acid, methylsulfonylmethane, NutriMinC and Softcap Fish Oil were analyzed by gas chromatography/mass spectrometry and manually screened for steroids using ultraviolet light. None of the samples were found to contain adulterants or contaminants.
Step 3: Classifying probable adverse effects Commonly used criteria for evaluating probable relationships between adverse events and the use of any product (or interactions between products) Practice E1086 CMAJ, October 4, 2011, 183(14) Areas of surviving hepatic parenchyma are summarized in Box 1. 16, 17 Adverse events that cannot be classified as probable can fall into one of the following three categories: possible; doubtful or unlikely; or unassessable or unclassifiable. A designation of unassessable or unclassifiable is usually due to a lack of information. Based on our review, we could not isolate a single causative agent. It is possible that it was the combination of medications, natural products and alcohol taken by our patient that led to her symptoms. Note: CFU = colony forming units, CLA = conjugated linoleic acid, DHA = docosahexaenoic acid, EPA = eicopentaenoic acid, OA = oleic acid, PA = palmitic acid, SA = stearic acid. *Product suggests it contains a blend of essential amino acids, but cysteine and tryptophan are not listed among the ingredients.
Identifying possible adverse reactions
As with other passive surveillance systems, MedEffect is subject to incomplete, inaccurate reporting and underreporting. For most reports of adverse effects, inferences regarding causality are not possible.
People often consider natural health products to be safe despite reported pharmacodynamic and pharmacokinetic interactions with conventional pharmaceuticals. 18 This perception of safety may mean there are fewer reports of suspected adverse events related to natural health products than reports of adverse events related to conventional medications. 17, 19 Because many Canadians use natural health products (and one third of Canadians report using more than three products concurrently), 20 it is prudent for physicians to ask about their use in the routine medical history and to consider potential interactions in a differential diagnosis when there is an unexpected response to treatment. Many natural health products may indeed be safe, and new Canadian regulations governing their labelling could help consumers be more wellinformed when choosing treatments. Still, when these products are combined with multiple prescription and nonprescription medications, serious problems can occur and caution is warranted. Physicians can help improve knowledge about these products by reporting suspected adverse reactions to the Canada Vigilance Program via MedEffect.
Natural health products are not regulated in the same way as prescription drugs, and information on which natural health product/drug combinations are safe and which are potentially associated with adverse events remains largely unknown. • The Naranjo scale: 16 A probable adverse reaction is indicated when there are previous reports of adverse reactions, when the onset of reaction is consistent with the time course of administration of the drug and when there is a positive response to withdrawal of the drug (dechallenge).
• The Horn Drug Interaction Probability Scale (DIPS): 17 A probable interaction is indicated when there are previous reports of interactions, when the reaction diminishes in a manner consistent with the time course of withdrawal of the drug, when there is a positive response to withdrawal of the drug (dechallenge) and when the interaction is consistent with the known pharmacology of the drug.
• World Health Organization (WHO) criteria: 16 A probable or likely adverse reaction is indicated if the clinical event occurs in a reasonable time frame after administration of the drug, if the event is unlikely to be due to concurrent disease and if the response to withdrawal of the drug (dechallenge) is clinically plausible. 
